Literature DB >> 3964792

Adrenal rest tumor of the liver causing Cushing's syndrome: treatment with ketoconazole preceding an apparent surgical cure.

P Contreras, E Altieri, C Liberman, A Gac, A Rojas, A Ibarra, M Ravanal, M Serón-Ferré.   

Abstract

Ketoconazole, an imidazole derivative known to inhibit cytochrome P450-dependent adrenal enzymes was given to a patient with a functioning adrenal rest tumor of the liver in preparation for surgery. The drug was administered in a stepwise manner for 42 days starting with 400 mg and reaching 1 g the last 4 weeks of the trial. Clear clinical improvement was evident early in the trial and was associated with evidence of amelioration of her hypercortisolism and striking changes in serum and urinary levels of steroid hormones and metabolites. Sex steroids in serum and urine fell dramatically from the first day to the end of the trial. Urinary 17-ketosteroid excretion fell from a basal average of 139 mg/24 h to near normal levels within a week of therapy; serum testosterone fell from a basal level of 2.4 to 0.18 ng/ml; serum 17 beta-estradiol fell likewise from 1096 to 150 pg/ml. In contrast, cortisol levels in serum and urine increased in the first 2 weeks of the trial and subsequently fell to values below the basal levels. Similarly, serum 17 alpha-OH-progesterone levels increased 63% above the basal levels by day 6 of the trial and declined afterwards. Nine months after successful tumor resection the patient is apparently cured as judged by steroid hormone levels and physical appearance. We conclude that ketoconazole was effective in blocking tumoral steroidogenesis which resulted in clinical benefit.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3964792     DOI: 10.1210/jcem-60-1-21

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Malignant adrenal rest tumor of the retroperitoneum producing adrenocortical steroids.

Authors:  Yuri Akishima-Fukasawa; Aya Yoshihara; Yukio Ishikawa; Natsuko Watanabe; Naoki Hiroi; Yoshikiyo Akasaka; Hironobu Sasano; Toshiharu Ishii; Gen Yoshino
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

2.  Adrenal function in paracoccidioidomycosis: a prospective study in patients before and after ketoconazole therapy.

Authors:  A Abad; I Gomez; P Velez; A Restrepo
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

3.  Preoperative ketoconazole therapy for adrenocortical carcinoma.

Authors:  L J Sinnaeve; G P Becks
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

Review 4.  The endocrine effects of ketoconazole.

Authors:  N Sonino
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

5.  Adrenal response to corticotropin during therapy with itraconazole.

Authors:  P Phillips; J R Graybill; R Fetchick; J F Dunn
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

6.  Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome.

Authors:  D Engelhardt; K Jacob; H G Doerr
Journal:  Klin Wochenschr       Date:  1989-02-15

Review 7.  Adrenocortical Carcinoma Arising in an Adrenal Rest: a Case Report and Review of the Literature.

Authors:  Kristine M Cornejo; Henrietta A Afari; Peter M Sadow
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

8.  Inhibition of human adrenal androgen secretion by ketoconazole.

Authors:  M M Weber; P Luppa; D Engelhardt
Journal:  Klin Wochenschr       Date:  1989-07-17

9.  Antitumor effects of ketoconazole and trifluoperazine in murine T-cell lymphomas.

Authors:  S Naftalovich; E Yefenof; Y Eilam
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  ACTH-independent Cushing's syndrome with bilateral micronodular adrenal hyperplasia and ectopic adrenocortical adenoma.

Authors:  Estelle Louiset; Françoise Gobet; Rossella Libé; Anelia Horvath; Sylvie Renouf; Juliette Cariou; Anya Rothenbuhler; Jérôme Bertherat; Eric Clauser; Philippe Grise; Constantine A Stratakis; Jean-Marc Kuhn; Hervé Lefebvre
Journal:  J Clin Endocrinol Metab       Date:  2009-11-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.